Notice of Results

RNS Number : 6647L
Venn Life Sciences Holdings PLC
23 April 2018
 

 

23 April 2018

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

 

Notice of Results

 

Venn Life Sciences (AIM: VENN) an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, will announce its audited preliminary results for the year ended 31 December 2017 on 17 May 2018.

 

The Company reaffirms its previous Trading Statement: 2017 was another solid year for Venn with the business delivering revenues of €17.8m (2016: €18.2m), broadly in line with market expectations, improved EBITDA performance and a closing cash position of €1.2m (2016: €3.4m).

 

Tony Richardson, Chief Executive Officer, and Christian Milla, Chief Operating Officer, will host a conference call and presentation for analysts at 09:30hrs BST at the offices of Walbrook PR. Details of the call will be published on the day of the results.

 

Enquiries:

 

Venn Life Sciences Holdings Plc

Allan Wood, Non-Executive Chairman

Tony Richardson, Chief Executive Officer

 

Tel: +353 1 549 9341

Cenkos (Nominated Advisor and Co-Broker)

Mark Connelly/Steve Cox (Corporate Finance)

 

Tel: +44 (0)20 3764 2341

Davy (ESM Adviser and Co-Broker)

Fergal Meegan / Matthew de Vere White (Corporate Finance)

 

Tel: +353 1 679 6363

Hybridan LLP (Co-Broker)

Claire Louise Noyce

 

Tel: +44 (0)20 3764 2341

Walbrook PR Ltd

Tel: +44 (0)20 7933 8787 or venn@walbrookpr.com

Paul McManus   

Mob: +44 (0)7980 541 893

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

 

 

About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn has dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

 

Further information in relation to Venn Life Sciences www.vennlifesciences.com

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORXBLFLVZFFBBD

Companies

Hvivo (HVO)
UK 100

Latest directors dealings